Press Releases Year None20262025202420232022202120202019 Jun 08, 2026 New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026 May 13, 2026 Century Therapeutics Reports First Quarter Financial Results and Business Updates Apr 30, 2026 Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions Mar 12, 2026 Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates Feb 25, 2026 Century Therapeutics to Participate in Upcoming Investor Conferences in March Jan 08, 2026 Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes Dec 09, 2025 Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors Nov 25, 2025 Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference Nov 13, 2025 Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Nov 13, 2025 Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 1 - 10 of 98
